NEW YORK (GenomeWeb News) – Harvard Bioscience today said it has formed a co-marketing and -development agreement with Nanoentek under which Nanoentek’s Digital Bio and HBIO’s BTX units will distribute certain of each others products in the US and in Asia.
HBIO’s BTX Harvard Apparatus business will distribute a gene-delivery system in the US made by Digital Bio, a Nanoentek segment.
Digital Bio in return will distribute BTX’s electroporation products in Asia.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.